Embecta (EMBC) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $272.5M, down 4.8% year-over-year, mainly due to distributor inventory normalization, timing of customer orders, and FX headwinds; results aligned with expectations and strategic priorities advanced.

• ERP and distribution network implementations now cover 93% of revenue, with full separation from BD expected by early FY2025.

• Progress made on FDA 510(k) submission for open-loop insulin delivery and development of closed-loop system for Type 2 diabetes, including FDA Breakthrough Device Designation.

• New small-pack pen needle product launched in Germany for GLP-1 users, with plans for further market expansion.

• Guidance for key financial metrics, including margins and EPS, was tightened and raised.

Financial highlights

• Q3 gross profit was $190.1M (69.8% margin), up from $189.5M (66.2%) last year; adjusted gross profit $190.3M (69.8%).

• Q3 operating income was $55.9M (20.5% margin), up from $51.3M (17.9%); adjusted operating income $83.3M (30.6% margin).

• Q3 net income was $14.7M ($0.25 EPS), slightly down from $15.2M ($0.26); adjusted net income $43.0M ($0.74 EPS), up from $39.8M ($0.69).

• Q3 adjusted EBITDA was $99.2M (36.4% margin), up from $92.2M (32.2%) last year.

• Cost of products sold in Q3 decreased 14.7% to $82.4M, improving gross margin.

Outlook and guidance

• FY24 revenue guidance: $1,111M–$1,116M, as-reported decline of 0.9% to 0.4%, constant currency flat to down 0.5%.

• Adjusted gross margin guidance raised to 65.25%–65.5%; adjusted operating margin to 25.75%–26.0%.

• Adjusted EBITDA margin guidance narrowed to 31.25%–31.5%.

• Adjusted EPS guidance increased to $2.30–$2.35.

• Separation-related cash outflows expected to decrease from $180M in FY2024 to ~$50M in FY2025, improving free cash flow.